MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo. by Horie, Takahiro et al.
Title
MicroRNA-33b knock-in mice for an intron of sterol regulatory
element-binding factor 1 (Srebf1) exhibit reduced HDL-C in
vivo.
Author(s)
Horie, Takahiro; Nishino, Tomohiro; Baba, Osamu; Kuwabara,
Yasuhide; Nakao, Tetsushi; Nishiga, Masataka; Usami,
Shunsuke; Izuhara, Masayasu; Nakazeki, Fumiko; Ide, Yuya;
Koyama, Satoshi; Sowa, Naoya; Yahagi, Naoya; Shimano,
Hitoshi; Nakamura, Tomoyuki; Hasegawa, Koji; Kume,
Noriaki; Yokode, Masayuki; Kita, Toru; Kimura, Takeshi;
Ono, Koh




This work is licensed under a Creative Commons Attribution
4.0 International License. The images or other third party
material in this article are included in the article's Creative
Commons license, unless indicated otherwise in the credit line;
if the material is not included under the Creative Commons
license, users will need to obtain permission from the license
holder in order to reproduce the material. To view a copy of




MicroRNA-33b knock-in mice for an
intron of sterol regulatory
element-binding factor 1 (Srebf1) exhibit
reduced HDL-C in vivo
Takahiro Horie1,2*, Tomohiro Nishino1*, Osamu Baba1, Yasuhide Kuwabara1, Tetsushi Nakao1,
Masataka Nishiga1, Shunsuke Usami1, Masayasu Izuhara1, Fumiko Nakazeki1, Yuya Ide1,
Satoshi Koyama1, Naoya Sowa1, Naoya Yahagi3, Hitoshi Shimano3, Tomoyuki Nakamura4,
Koji Hasegawa5, Noriaki Kume6, Masayuki Yokode2, Toru Kita7, Takeshi Kimura1 & Koh Ono1
1Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan, 2Department of
Clinical Innovative Medicine, Institute for Advancement of Clinical and Translational Science, Graduate School of Medicine, Kyoto
University, Kyoto 606-8507, Japan, 3Department of Internal Medicine (Endocrinology and Metabolism), Graduate School of
Comprehensive Human Sciences, Nutrigenomics Research Group, Faculty of Medicine, and International Institute for Integrative
Sleep Medicine (IIIS), World Premir International Research Center Initiative (WPI), University of Tsukuba, 1-1-1 Tennodai, Tsukuba,
Ibaraki 305-8575, Japan, 4Department of Pharmacology, Kansai Medical University, Moriguchi, Osaka 570-8506, Japan,
5Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan, 6Division of
Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe 650-8586, Japan, 7Department of
Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe 650-0046, Japan.
MicroRNAs (miRs) are small non-protein-coding RNAs that bind to specific mRNAs and inhibit
translation or promote mRNA degradation. Recent reports, including ours, indicated that miR-33a located
within the intron of sterol regulatory element-binding protein (SREBP) 2 controls cholesterol homeostasis
and can be a possible therapeutic target for treating atherosclerosis. Primates, but not rodents, express
miR-33b from an intron of SREBF1. Therefore, humanized mice, in which a miR-33b transgene is inserted
within a Srebf1 intron, are required to address its function in vivo. We successfully established miR-33b
knock-in (KI) mice and found that protein levels of known miR-33a target genes, such as ABCA1, ABCG1,
and SREBP-1, were reduced compared with those in wild-type mice. As a consequence, macrophages from
the miR-33b KI mice had a reduced cholesterol efflux capacity via apoA-I and HDL-C. Moreover, HDL-C
levels were reduced by almost 35% even in miR-33b KI hetero mice compared with the control mice. These
results indicate that miR-33b may account for lower HDL-C levels in humans than those in mice and that
miR-33b is possibly utilized for a feedback mechanism to regulate its host gene SREBF1. Our mice will also
aid in elucidating the roles of miR-33a/b in different genetic disease models.
S
terol regulatory element-binding proteins (SREBPs) comprise a subclass of basic helix-loop-helix leucine
zipper transcription factors conserved from yeasts to humans and regulate the expression of genes required
for maintaining cellular lipid homeostasis1. Mammals possess two SREBP genes, SREBP-1 and SREBP-2
(known as SREBF1 and SREBF2, respectively) that express three major SREBP proteins. Two SREBP-1 isoforms,
SREBP-1a and SREBP-1c, primarily regulate fatty acid metabolism, and SREBP-2 is the main regulator of
cholesterol metabolism, although there is some functional overlap among the three SREBP isoforms2–4.
MicroRNAs (miRs) are small non-protein-coding RNAs that bind to specific mRNAs and inhibit translation
or promote mRNA degradation5. Recent advances in the understanding of miR biology revealed that the genetic
loci encoding for the transcription factors SREBP-1 and SREBP-2 also encode for the miRs miR-33b and miR-
33a, respectively. Recent reports, including ours, indicated that miR-33a controls ABCA1 expression and reduces
HDL-C levels6–8 and that miR-33a deficiency ameliorates atherosclerosis in mice9–11. However, in rodents, a part
of miR-33b is lacking from a Srebf1 intron (Supplementary Fig. 1a), and it is impossible to determine the precise
coordinate mechanisms of miR-33a andmiR-33b; the expression of these miR-33s is expected to depend on their
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challenges, or statin treatment, and the amounts and functions of
miR-33a and miR-33b would be greatly affected under these
conditions.
miR-33a and miR-33b are identical in their seed sequences, and
thus have been predicted to repress the same set of genes with similar
specificities. Antisense oligonucleotides against miR-33a are believed
to simultaneously target miR-33a and miR-33b. However, there
remains a 2-nucleotide mismatch after the seed sequence between
miR-33a and miR-33b (Supplementary Fig. 1a), and whether this
difference results in differential targeting remains to be established.
Moreover, some of the previously established miR-33a target genes
were not dysregulated in our miR-33a-deficient mice. Therefore,
humanized mice, in which a miR-33b transgene is inserted within
a Srebf1 intron, are required to address its function in vivo.
We successfully established miR-33b knock-in (KI) mice for the
same intron as in humans. The protein levels of known miR-33a
target genes, such as ABCA1, ABCG1, and SREBP-1, were reduced
under basal conditions. An LXR agonist, which induces Srebf1
expression, enhanced miR-33b production. In vitro experiments
indicated thatmacrophages from themiR-33bKImice had a reduced
cholesterol efflux capacity via apoA-I and HDL-C. Moreover, HDL-
C levels were reduced by almost 35% even inmiR-33b KI heteromice
compared with the control mice.
The feasibility of genetic manipulation is one of the many advan-
tages of using mice as a model organism. However, the lack of miR-
33b in mouse Srebf1 has raised an important concern regarding the
direct translation of data from rodent models to human physiology
and metabolic disorders. Our mice will aid in answering these ques-
tions and will be useful for assessing the risks and benefits of long-
term alterations in miR-33s in different disease models. These mice
might also be useful for screening of the drugs that alter the levels of
miR-33a and miR-33b.
Results
miR-33b is co-expressed with SREBF1 in the human cell line HepG2.
It is assumed that a miR located within an intron of a gene is ex-
pressed along with its host gene and exerts its specific function12.
Because miR-33b is located in a SREBF1 intron in humans (Supple-
mentary Fig. S1a), we stimulated human cell line HepG2 with the
LXR agonist T0901317 and determined miR-33b and miR-33a
expression along with the expression of the host genes SREBF1
and SREBF2. As shown in Fig. 1a and b, miR-33b expression
seemed to tag along behind SREBF1 expression. In contrast, miR-
33a and SREBF2 expression was not affected by LXR stimulation
(Fig. 1c and d).
Generation of miR-33b KI mice. Because miR-33b is located in
SREBF1 intron 16 in humans and there are high homologies in
exons 16 and 17 between human and mouse (82.6% of nucleotides
and 79.7% of amino acids, Supplementary Fig. S1b), we introduced
the human miR-33b sequence into intron 16 of mouse Srebf1. We
isolated and amplified the region that encoded for the complete pre-
miR sequence of human miR-33b and adjacent sequence, which
enabled the introduction of miR-33b into intron 16 of mouse
Srebf1 (Fig. 2a). Supplementary Figure S2a and Figure 2b show the
results of Southern blotting analysis of genomic DNA from ES cells
and tail genomic DNA from F1 mice that were successfully targeted
by a KI vector, respectively. PCR analysis indicated the specific
patterns for wild-type (WT), KI1/2, and KI1/1 mice (Fig. 2c). This
miR-33b KI strategy did not alter Srebf1 intron 16 splicing, as
confirmed by PCR (Fig. 2d) and sequencing (Fig. 2e). The
expression levels of miR-33b in miR-33b KI1/2 mice were almost
half of those in miR-33b KI1/1 mice (Fig. 2f). We also measured the
levels of miR-33b, miR-33a, Srebf1, and Srebf2 inWT and KI mice in
both the liver and the peritoneal macrophages (Supplementary
Figure S2b–d and S3a–d). Srebf1 levels were similar among these
mice (Supplementary Figure S2c and S3c). Although there was no
difference in miR-33a levels in macrophages (Supplementary Figure
S3b), miR-33a levels were increased in proportion of the expression
levels of miR-33b in the liver (Supplementary Figure S2b). The miR-
33b KI1/1 mice were born with the expected Mendelian ratios, were
viable, fertile, and did not exhibit any obvious abnormalities in size,
shape, or structure up to 8 weeks of age. Relative tissue expression
pattern of miR-33b was similar to that of Srebf1 (Supplementary Fig.
S2e and S2f).
miR-33b is upregulated after inducing Srebf1 expression.We next
sought to confirm whether miR-33b expression was affected by
endogenous changes in Srebf1 expression by the LXR agonist
T090131713. When primary hepatocytes from the miR-33b KI1/1
mice were stimulated with T0901317, Srebf1 and miR-33b mRNA
levels were significantly increased in parallel, although this increase
was faster for Serbf1 than for miR-33b (Fig. 3a and b). To check this
effect in vivo, T0901317 was suspended in 0.5% carboxymethyl-
cellulose and administrated to 8-week-old male miR-33b KI1/1
mice at a dose of 25 mg/kg for 3 days. The average liver weight of
the T0901317-treated mice was 1.5-fold greater than that of the
control mice (Supplementary Fig. S4a). Srebf1 and miR-33b
expression levels in the liver were also significantly increased in
parallel (Fig. 3c and d). The average liver weight and Srebf1
expression level in the liver of T0901317-treated WT mice were
shown in Supplementary Figure S4b and S4c. These results
indicate that miR-33b was co-expressed with Srebf1 in the livers of
the T0901317-treated miR-33b KI mice.
miR-33b KI results in alterations in miR-33a target proteins
ABCA1 and SREBP-1. We determined ABCA1, SREBP-1, CPT1a,





























































Figure 1 | miR-33b is co-expressed with SREBF1 in HepG2 cells.HepG2 cells were treated with T0901317 (10 mM) for the indicated time. The relative
expressions of SREBF1 (a), miR-33b (b), SREBF2 (c), and miR-33a (d) are shown (n 5 6–9). Values are mean 6 s.e.m. *p , 0.05, ***p , 0.001
compared with 0 h.
www.nature.com/scientificreports
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Figure S5). As shown in Fig. 4a, Supplementary Figure S5a, and S5b,
ABCA1 and SREBP-1 protein levels were lower in the livers of the
miR-33b KI mice. However, the protein levels of some of the
previously defined miR-33a target genes, such as CPT1a and
AMPKa remained unchanged. We also analyzed protein expres-
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Figure 2 | Generation of miR-33b knock-in (KI) mice. (a). Strategy used to generate miR-33b KI mice. (b). Southern blotting of mouse tail genomic
DNA. Representative images are shown. (c). PCR analysis of mouse tail genomic DNA. Representative images are shown. (d). RT-PCR analysis of Srebf1
expression in the livers of 8-week-old mice. Sense primer was designed for exon 13, and antisense primer was designed for exon17. Note that there was no
other band except for that of the correct size. Representative images are shown. (e). Sequencing alignment at the joint between exons 16 and 17 of Srebf1 in







































































Figure 3 | miR-33b is co-expressed with Srebf1 in miR-33b KI mice. (a). Relative Srebf1 expression levels in primary hepatocytes from miR-33b KI1/1
mice treated with T0901317 (10 mM) for the indicated time. Values are mean 6 s.e.m (n 5 6). **p, 0.01 ***p, 0.001 by one-way analysis of variance.
(b). Relative miR-33b expression levels in primary hepatocytes frommiR-33b KI1/1 mice treated with T0901317 (10 mM) for the indicated time. Values
aremean6 s.e.m (n5 6). **p, 0.01 by one-way analysis of variance. (c). Relative Srebf1 expression levels in the livers of 8-week-oldmalemiR-33b KI1/1
mice treated with T0901317 (25 mg/kg) for 3 days. Values are means 6 s.e.m (n 5 6). **p , 0.01 compared with the vehicle. (d). Relative miR-33b
expression levels in the livers of 8-week-old male miR-33b KI1/1 mice treated with T0901317 (25 mg/kg) for 3 days. Values are mean 6 s.e.m (n 5 6).
*p , 0.05 compared with the vehicle.
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Figure S5c–f). However, no significant change in protein level was
observed in PCK1, G6PC, and CREB in the liver of miR-33b KI mice
compared with that of control mice. SRC1 was up-regulated in miR-
33bKI mice and it was opposite to the results of previous report14.
miR-33b KI reduces cholesterol efflux in macrophages. To inves-
tigate a physiological role of miR-33b in mice, we first compared the
functions of peritoneal macrophages from the WT and miR-33b
KI1/1 mice. ABCA1 and ABCG1 protein levels were lower in
macrophages from the miR-33b KI1/1 mice than from the WT
mice (Fig. 5a and Supplementary Figure S3e and S3f), which was
compatible with the findings for our miR-33a-deficient mice. We
determined apoA-I- and HDL-C-mediated cholesterol efflux from
peritoneal macrophages and found that macrophages from the miR-
33b KI1/1 mice had lower apoA-I- and HDL-C-mediated cholesterol
efflux than those from the WT mice (Fig. 5b).
A single miR-33b copy reduces serumHDL levels.Hepatic ABCA1
overexpression increases HDL-C levels15, and liver-specific deletion
of ABCA1 results in a substantial decrease in plasma HDL-C levels
(approximately 80%) in chow-fed mice16. Moreover, we previously
reported that the miR-33a2/2 mice had 22%–39% higher serum
HDL-C levels than the WT mice8. Thus, we determined the serum
HDL-C levels of theWT,miR-33b KI1/2, andmiR-33b KI1/1 mice at
the age of 8 weeks.
Serum HDL-C levels were significantly decreased in the miR-33b
KI1/2 andmiR-33b KI1/1 mice compared with theWTmice (Table).
We also classified and quantified serum lipoproteins using high-
performance liquid chromatography (HPLC). Mean plots of the
HPLC elution profile of serum from male mice are shown in
Fig. 5c, and the lipid profiles are summarized in Supplementary
Table S1. These results show that only one copy of miR-33b was
sufficient to substantially reduce HDL-C and total cholesterol to
the same levels as those in the miR-33b KI1/1 mice. Moreover, the
decreasedHDL levels mainly comprised very large-, large-, andmed-
ium-sized HDLs (mature HDLs) (Fig. 5c and Supplementary Table
S1).
Discussion
In the present study, we successfully established humanized mice, in
which a miR-33b transgene was inserted within the same intron as
that in human SREBF1. The LXR agonist T0901317, which is a well-
established Srebf1 expression inducer, enhanced miR-33b produc-
tion. The protein levels of known miR-33a/b target genes, such as
ABCA1, ABCG1, and SREBP-1, were reduced under basal condi-
tions. In vitro experiments indicated that macrophages from the
miR-33b KI1/1 mice had a reduced cholesterol efflux capacity via
apoA-I and HDL-C. Finally, HDL-C levels were reduced by almost
35% even in the miR-33b KI1/2 mice compared with the WT mice
without any changes in triglyceride (TG) levels.
In contrast to humans and other mammals, rodents lack miR-
33b and only have miR-33a in Srebf2. This needs to be kept in
mind when attempting to directly translate to humans the previous
results that miR-33a inhibition could prevent atherosclerosis in
mouse models because of two reasons. First, SREBF1 and
SREBF2 are differentially regulated by hormones, dietary chal-
lenges, and lipid-lowering agents, including statins17. This indicates
that both isoforms of miR-33 participate in regulating the primary
risk factors of metabolic syndrome, which accelerate atheroscler-
osis. Second, miR-33b differs from miR-33a by 2-nucleotides and
may have a different target profile, including stronger effects on
targets in the SREBP-1-dependent regulation of fatty acid/TG
homeostasis and insulin signaling. We found increased miR-33b
expression after treatment with LXR agonist in our mice, which
indicated that miR-33b was co-expressed with its Srebf1 host gene
and enabled us to study the impact of Srebf1-derived miR-33b on
cholesterol/lipid homeostasis.
We have not yet succeeded in identifying miR-33b-specific target
genes. Even previously reported miR-33b target genes were not
reduced in the liver of miR-33b KI mice compared with that of
control mice. One of the reasons of such result may be that the
previous study was conducted in human cell line and potential bind-
ing sites of miR-33b are not conserved at least in PCK1 39UTR of
mice. It is also possible that some compensated mechanisms may
have occurred in miR-33b KI mice. However, the protein levels of
miR-33a target genes, such as ABCA1, ABCG1, and SREBP-1, were
reduced18. Moreover, the protein levels of previously defined miR-
33a target genes, which were not dysregulated in miR-33a KO mice,
including CPT1a and AMPKa, remained unchanged19,20. Thus, it
may be necessary to assess those conditions when Srebf1 expression
is strongly affected to establish the importance of the functions of
miR-33b. In any event, the numbers of miR-33b transcripts were
greater than those of miR-33a transcripts, and this underscores the
importance of miR-33b21. Although there were no differences in the
levels of miR-33a in macrophages, it is interesting that the levels of
miR-33a were increased in proportion to the expression levels of
miR-33b in the liver. Because Srebf1 level is higher in the liver than
that in macrophages22, it is possible that miR-33b andmiR-33a com-
pete for the same target gene binding sites in the liver, and that the
degradation of miR-33a is inhibited by miR-33b expression. In addi-
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Figure 4 | miR-33b regulates ABCA1 and SREBP-1. (a). Western blotting analysis for ABCA1, SREBP-1, CPT1a, and AMPKa protein levels in the
livers ofWT, KI1/2, and KI1/1 mice. Representative images are shown. TF2B and b-actin were used as loading controls. (b). Western blotting analysis for
SRC1, PCK1, CREB and G6Pase protein levels in the livers of WT, KI1/2, and KI1/1 mice. Representative images are shown. b-actin were used as loading
controls.
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miRs are known to target long non-coding RNAs whose functions
are largely unknown, and interactions between miRs are also pos-
sible23. Thus, miR-33b-specific functions should be determined in
future experiments.
Rayner et al. recently showed that inhibiting miR-33a and miR-
33b in healthy male non-human primates increased circulating
HDL-C levels21. More recently, Rottiers et al. reported that miR-
33a and miR-33b acted in a redundant manner and that inhibiting
both isoforms by an 8-mer LNA-modified anti-miR enhanced HDL-
C levels24. Our data demonstrated that miR-33b indeed functions to
control HDL-C levels, which highlights the importance of targeting
both miR-33 family members simultaneously. It is noteworthy that
only one copy of miR-33b (miR-33b KI1/2 mice) significantly
reduced HDL-C levels to the same levels as those in the miR-33b
KI1/1 mice. This explains one of the reasons why human HDL-C
levels are lower than those of mice and indicates that it is important
to considerably reduce miR-33b levels if pharmacological targeting
of miR-33s is used to increase HDL-C levels. In this context, the
current LNA-modified anti-miR technique is quite potent for redu-
cing the levels of both miR-33 isoforms and may be useful for anti-
atherosclerosis therapy.
In addition to the effects on HDL-C, a study by Rayner et al.
showed that miR-33 antagonism reduced very low-density lipopro-
tein-associated TGs in their cohort of normal male African green
monkeys21. However, Rottiers et al. did not find any significant
changes in TG levels when using miR-33a/b-targeting LNA-anti-
miR treatment24. In our present miR-33b KI study and in previous
miR-33a KO experiments8, we did not observe any changes in TG
levels, indicating that modulation of miR-33s is unlikely to have a
strong effect on TG levels, although species differences and different
dietary conditions need to be considered.
In contrast, we found a significant inhibitory effect of miR-33b on
SREBP-1. A feedback system of SREBP-2 by cholesterol levels is well













































Figure 5 | miR-33b reduces cellular cholesterol efflux and serum HDL-C levels. (a). Western blotting for ABCA1 and ABCG1 proteins in peritoneal
macrophages from WT and KI1/1 mice. Representative images are shown. b-actin was used as the loading control. (b). Cholesterol efflux to apoA-I
and HDL-C in peritoneal macrophages fromWT and KI1/1 mice (n 5 6 each). Values are mean 6 s.e.m. ***p, 0.001 (c). Mean plots of HPLC analysis
for serum cholesterol in WT and KI1/1 mice (n 5 4 and 5, respectively).
Table | Serum profiling of WT, KI1/2, and KI1/1 mice
WT (n 5 4) KI1/2 (n 5 4) KI1/1 (n 5 4)
TP (g/dL) 4.375 6 0.1109 4.275 6 0.04787 4.350 6 0.05000
ALB (g/dL) 2.950 6 0.1190 2.825 6 0.1109 2.900 6 0.04082
BUN (mg/dL) 21.75 6 0.6801 20.58 6 1.248 21.58 6 1.680
CRE (mg/dL) 0.1125 6 0.002500 0.0925 6 0.004787 * 0.0975 6 0.006292
Na (mEq/L) 152.5 6 0.6455 153.5 6 0.2887 153.8 6 0.4787
K (mEq/L) 3.350 6 0.05000 3.325 6 0.0750 3.350 6 0.1041
Cl (mEq/L) 110.5 6 0.6455 110.8 6 0.2500 111.0 6 0.5774
Ca (mg/dL) 8.500 6 0.1871 8.325 6 0.1109 8.350 6 0.08660
IP (mg/dL) 7.775 6 0.4589 7.225 6 0.2955 7.400 6 0.4637
T-BIL (mg/dL) 0.0875 6 0.004787 0.0925 6 0.008539 0.0825 6 0.01109
AST (IU/L) 39.25 6 1.702 33.50 6 1.658 39.25 6 1.702
ALT (IU/L) 26.50 6 3.663 21.00 6 2.415 22.75 6 1.702
ALP (IU/L) 505.5 6 48.55 398.5 6 40.01 480.0 6 29.31
LDH (IU/L) 278.3 6 77.21 243.5 6 55.30 255.0 6 55.26
AMY (IU/L) 2295 6 68.22 2224 6 62.39 2363 6 97.02
c-GTP (IU/L) 3. 3. 3.
T-CHO (mg/dL) 98.50 6 5.694 66.25 6 2.287 ** 62.00 6 1.225 ***
TG (mg/dL) 34.75 6 2.780 32.25 6 3.065 35.25 6 4.328
NEFA (mEq/L) 471.0 6 47.36 474.8 6 71.81 459.5 6 55.01
LDL-C (mg/dL) 6.750 6 0.6292 6.750 6 0.6292 6.000 6 0.0
HDL-C (mg/dL) 57.75 6 4.171 39.25 6 0.7500 ** 37.25 6 0.6292 **
GLU (mg/dL) 216.3 6 22.98 180.5 6 8.930 197.8 6 11.92
Values are mean 6 s.e.m. Blood was obtained from chow-fed 8-wk-old male mice after 4 h fasting.
*p , 0.05;
**p , 0.01;
***p , 0.001 compared with WT mice.
www.nature.com/scientificreports
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However, a similar mechanism has not been established for SREBP-
1. Chronic activation of SREBP-1c in cases of overnutrition can lead
to serious obesity-related problems. miR-33b may be utilized for a
feedback mechanism to regulate its host gene SREBF1 because insu-
lin induces hepatic SREBP-1c expression and promotes lipogenesis
and hepatic TG synthesis (Supplementary Fig. S6).
In the present study, we demonstrated the effect of miR-33b on
HDL-C levels in vivo. We assume that inhibiting both miR-33a and
miR-33b will have a significant effect on HDL-C levels in clinical
settings. However, it is known that one miR can have hundreds of
target genes and unexpected side effects may occur due to long-term
therapeutic modulation of miR-33 to cure metabolic diseases.
Careful observations of miR-33b KI and miR-33a-deficient mice
and intercrossing of these mice will enable us to detect miR-33a-
and miR-33b-specific target genes and to elucidate the overall func-
tions of miR-33a andmiR-33b in vivo. Moreover, ourmice will aid in
analyzing the roles of miR-33a/b in different genetic disease models
and in screening drug candidates that can modulate miR-33a and
miR-33b levels and activities.
Methods
Materials. The following antibodies were used: anti-ABCA1 (NB400-105) and anti-
ABCG1 (NB400-132) (Novus Biologicals, Littleton, CO, USA); anti-AMPKa (#2532)
and anti-CREB (#9197) (Cell Signaling Technology, Beverly, MA, USA); anti-CPT1a
(ab128568) and anti-PCK1 (ab70358) (Abcam, Cambridge, UK); anti-b-actin (AC-
15; A5441, Sigma-Aldrich, St. Louis, MO, USA); anti-SREBP-1 (sc-13551, sc-8984),
anti-SRC1 (sc-8995), anti-G6Pase (sc-27198), and anti-TF2B (sc-225) (Santa Cruz,
Biotechnology, California, USA). Anti-mouse, anti-rabbit and anti-goat IgG HRP-
linked antibodies were purchased from GE Healthcare (Amersham, UK). Human
apoA-I was purchased from Sigma-Aldrich. Human acetylated LDL (acLDL) and
humanHDL-Cwere purchased fromBiomedical Technologies, Inc. (Stoughton,MA,
USA). [1, 2-3H (N)]-Cholesterol was purchased from Perkin Elmer (Boston, MA,
USA). T0901317 was purchased from Cayman Chemical (Ann Arbor, MI, USA).
Generation of miR-33b KI mice. A targeting vector was constructed by modifying
bacterial artificial chromosome RP24-310C22 (Invitrogen) using a defective
prophage l-Red recombination system25,26. As a selection marker, a neomycin
resistance cassette flanked by loxP sites (loxP-PGK-gb2-neo-loxP cassette; Gene
Bridges, Germany) was inserted at the adjacent site of the human pre-miR-33b site.
The targeting vector was electroporated into C57BL/6 mouse ES cells (DS Pharma
Biomedical) using a Nucleofector system (Lonza). Positive clones were selected by
incubating cells with 200 mg/ml geneticin (Invitrogen) for 5 days, and homologous
recombination was confirmed by Southern blotting. Successfully recombined ES cells
were injected into blastocysts from ICR strain mice supplied by Unitech Inc. (Japan),
and chimeric mice were bred with C57BL/6 mice to generate F1 mice. F1 mice
genotypes were confirmed by Southern blotting. The neomycin resistance cassette
was removed from the mouse germ line by breeding heterozygous mice with Ayu-1
CreKImice, which expressed Cre recombinase inmultiple tissues, including the germ
line27. Descendant miR-33b knock-in heterozygous mice without theAyu-1 Cre allele
were crossed with each other to generate the miR-33b KI1/1 mice. All experiments
were performed with male C57BL/6 background mice and wild-type littermates were
used as a control. All of the experimental protocols were approved by the Ethics
Committee for Animal Experiments of Kyoto University and the methods were
performed in accordance with the guidelines approved by the ethics committee.
Primers used for genotyping were as follows: WT/KI sense, ATGGATTTACC-
TCAGTTTTAACGAC; WT antisense, CATCACTGAAGCACTGCATCTGC; KI
antisense, AAGTGGATCCAGAATTCGTGA; Cre sense, GCTGCCACGACdC-
AAGTGACAGCAATG; and Cre antisense, GTAGTTATTCGGATCATCAGC-
TACAC.
Southern blotting. Southern blotting was performed using DIG High Prime DNA
Labeling and Detection Starter Kit II (Roche) according to the manufacturer’s
protocol. Genomic DNA samples were purified and digested withMfeI and AseI for a
59 probe, EcoRI for a 39 probe, and NheI for a Neo probe. Primer sequences used to
amplify these probes were as follows:
59 probe sense, CACGGTTGTGAGAAGTCAGTATTC; 59 probe antisense,
CTTTGCAAGCTCCTTGAGAATAAG; 39 probe sense, AGTAAAATTCTCCTC-
AATGAACGTG; 39 probe antisense, CAGTAGGTGACATTGTGATTGATCT; Neo
probe sense, GAACAAGATGGATTGCACGCAGGTTCTCCG; and Neo probe
antisense, GTAGCCAACGCTATGTCCTGATAG.
Determination of splicing between exons 16 and 17 in Srebf1. We amplified the
fragment between Srebf1 exons 13 and 17 using cDNA from the livers of the indicated
mice by PCR, and these products were then electrophoresed. Extension time was
sufficient to expand the fragment when the correct splicing did not occur. There was
no other band except for that of the correct size. Sequencing was performed using a
primer for exon 16 and an ABI 3130 genetic analyzer. Primer sequences used were as
folows:
Exon 13 sense, CCTAGAGCGAGCGTTGAACT; Exon 17 antisense, CTACCT-
GGACTGAAGCTGGTG; and Exon 16 sequence primer, AGGGCAGCTCTGTAC-
TCCTTC.
Cell culture. HepG2 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Nacalai Tesque, Japan) supplemented with 10% fetal bovine serum (FBS).
Mouse primary hepatocytes were obtained from miR-33b KI1/1 mice using a two-
step collagenase perfusion method28. In brief, hepatocyte suspensions were obtained
by passing a collagenase type II (Gibco BRL, Life Technologies Inc., Rockville, MD,
USA)-digested liver sample through a 70-mm cell strainer, followed by centrifugation
to isolate mature hepatocytes. Hepatocytes were then resuspended in DMEM
supplemented with 10% FBS and seeded on collagen type I-coated dishes (Iwaki
Asahi Glass Co. Ltd., Japan) at a density of 73 104 cells/ml. After incubation for 24 h,
the cells were used for experiments.
Cholesterol efflux from macrophages. Cellular cholesterol efflux via apoA-I was
determined as described previously29. In brief, thioglycollate-elicited mouse
peritoneal macrophages were plated in 24-well microplates at a density of 5 3
106 cells/ml. Cells were cultured for 24 h in RPMI 1640 containing 3H-labeled acLDL
(1.0 mCi/ml of 3H-cholesterol and 25 mg/ml of acLDL). On the next day, the cells
were washed 3 times with RPMI 1640 and incubated for 6 h in RPMI 1640 with or
without apoA-I (10 mg/ml) or HDL (100 mg/ml). Cholesterol efflux was expressed as
the percentage of radioactivity released from cells in medium relative to the total
radioactivity in cells plus medium.
Western blotting. Western blotting was performed using standard procedures as
described previously30. A lysis buffer was supplemented with a complete mini
protease inhibitor (Roche), ALLN (25 mg/ml), 0.5 mMNaF, and 10 mMNa3VO4 just
prior to use. Protein concentrations were determined using a bicinchoninic acid
protein assay kit (Bio-Rad). All samples (20 mg of protein) were suspended in lysis
buffer, fractionated using NuPAGE 4%–12% Bis-Tris (Invitrogen) gels, and
transferred to a Protran nitrocellulose transfer membrane (Whatman). The
membrane was blocked using 13 phosphate-buffered saline (PBS) containing 5%
non-fat milk for 1 h and incubated with a primary antibody [anti-ABCA1 (151000),
anti-ABCG1 (151000), anti-AMPKa (151000), anti-SREBP-1 (15250), anti-TF2B
(151000), anti-b-actin (153000), anti-CREB (151000), anti-PCK1 (151000), anti-
SRC1 (15200), anti-G6Pase (15200) or anti-CPT1a (151000)] overnight at 4uC. After
washing with PBS–0.05% Tween 20 (0.05% T-PBS), the membrane was incubated
with a secondary antibody (anti-rabbit, anti-mouse and anti-goat IgG HRP-linked;
152000) for 1 h at 4uC. The membrane was then washed with 0.05% T-PBS and
detected with an ECLWestern Blotting Detection Reagent (GE Healthcare) using an
LAS-1000 system (Fuji Film).
RNA extraction and quantitative RT-PCR (qRT-PCR).Total RNAwas isolated and
purified using TriPure Isolation Reagent (Roche). cDNA was synthesized from 1 mg
of total RNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche)
according to the manufacturer’s instructions. For qRT-PCR, specific genes were
amplified in 40 cycles using SYBRTM Green PCR Master Mix (Applied Biosystems).
Expression was normalized to that of the housekeeping gene b-actin. Gene-specific
primers are as follows;
SREBF1 sense, AACAGTCCCACTGGTCGTAGAT; SREBF1 antisense,
TGTTGCAGAAAGCGAATGTAGT; SREBF2 sense, AGGAGAACATGGTG-
CTGA; SREBF2 antisense, TAAAGGAGAGGCACAGGA; ACTB sense, AGGCA-
CTCTTCCAGCCTTCC; ACTB antisense, GCACTGTGTTGGCGTACAGG; Srebf1
sense, TAGAGCATATCCCCCAGGTG; Srebf1 antisense, GGTACGGGCCAC-
AAGAAGTA; Srebf2 sense, GTGGAGCAGTCTCAACGTCA; Srebf2 antisense,
TGGTAGGTCTCACCCAGGAG; Actb sense, GATCTGGCACCACACCTTCT;
and Actb antisense, GGGGTGTTGAAGGTCTCAAA.
Quantitative PCR for miRs. Total RNA was isolated using the TriPure Isolation
Reagent (Roche). miR-33a and miR-33b were measured using TaqMan MicroRNA
assay protocols (Applied Biosystems). Products were analyzed using a thermal cycler
(ABI PrismH 7900HT sequence detection system). miRs expression of samples were
normalized by U6 snRNA expression.
Serum biochemical analysis. After mice were fasted for 4–6 h, blood was obtained
from the inferior vena cava of an anesthetized mouse, and serum was separated by
centrifugation at 4uC and stored at 280uC. Employing standard methods, biochemical
measurements were made using a Hitachi 7180 Auto Analyzer (Nagahama Life
Science Laboratory, Nagahama, Japan). Lipoproteins were analyzed by HPLC at
Skylight Biotech (Akita, Japan), according to the procedures described previously31.
Statistical analysis. Results are given as mean 6 s.e.m. Statistical comparisons were
made using unpaired two-tailed Student’s t-tests or one-way analysis of variance with the
Bonferroni post hoc test, as appropriate. A p value of,0.05 was considered significant.
1. Osborne, T. F. & Espenshade, P. J. Evolutionary conservation and adaptation in
the mechanism that regulates SREBP action: what a long, strange tRIP it’s been.
Genes Dev 23, 2578–2591 (2009).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5312 | DOI: 10.1038/srep05312 6
2. Espenshade, P. J. & Hughes, A. L. Regulation of sterol synthesis in eukaryotes.
Annu Rev Genet 41, 401–427 (2007).
3. Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete
program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109,
1125–1131 (2002).
4. Yokoyama, C. et al. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that
controls transcription of the low density lipoprotein receptor gene. Cell 75,
187–197 (1993).
5. Ono, K., Kuwabara, Y. &Han, J. MicroRNAs and Cardiovascular Diseases. FEBS J
(2011).
6. Najafi-Shoushtari, S. H. et al. MicroRNA-33 and the SREBP host genes cooperate
to control cholesterol homeostasis. Science 328, 1566–1569 (2010).
7. Rayner, K. J. et al. MiR-33 contributes to the regulation of cholesterol homeostasis.
Science 328, 1570–1573 (2010).
8. Horie, T. et al. MicroRNA-33 encoded by an intron of sterol regulatory element-
binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci U S A 107,
17321–17326 (2010).
9. Rayner, K. J. et al. Antagonism of miR-33 in mice promotes reverse cholesterol
transport and regression of atherosclerosis. J Clin Invest 121, 2921–2931 (2011).
10. Horie, T. et al. MicroRNA-33 Deficiency Reduces the Progression of
Atherosclerotic Plaque in ApoE(2/2) Mice. J AmHeart Assoc 1, e003376 (2012).
11. Horie, T. et al. MicroRNAs and LipoproteinMetabolism. J Atheroscler Thromb 21,
17–22 (2014).
12. Sowa, N. et al. MicroRNA 26b encoded by the intron of small CTD phosphatase
(SCP) 1 has an antagonistic effect on its host gene. J Cell Biochem 113, 3455–3465
(2012).
13. DeBose-Boyd, R. A., Ou, J., Goldstein, J. L. & Brown, M. S. Expression of sterol
regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells
requires endogenous LXR ligands. Proc Natl Acad Sci U SA 98, 1477–1482 (2001).
14. Ramirez, C.M. et al. MicroRNA33 regulates glucosemetabolism.Mol Cell Biol 33,
2891–2902 (2013).
15. Basso, F. et al. Role of the hepatic ABCA1 transporter in modulating intrahepatic
cholesterol and plasma HDL cholesterol concentrations. J Lipid Res 44, 296–302
(2003).
16. Timmins, J. M. et al. Targeted inactivation of hepatic Abca1 causes profound
hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest
115, 1333–1342 (2005).
17. Shimano, H. SREBPs: physiology and pathophysiology of the SREBP family. FEBS
J 276, 616–621 (2009).
18. Horie, T. et al. MicroRNA-33 regulates sterol regulatory element-binding protein
1 expression in mice. Nat Commun 4, 2883 (2013).
19. Gerin, I. et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol
export and fatty acid oxidation. J Biol Chem 285, 33652–33661 (2010).
20. Fernandez-Hernando, C. & Moore, K. J. MicroRNA modulation of cholesterol
homeostasis. Arterioscler Thromb Vasc Biol 31, 2378–2382 (2011).
21. Rayner, K. J. et al. Inhibition of miR-33a/b in non-human primates raises plasma
HDL and lowers VLDL triglycerides. Nature 478, 404–407 (2011).
22. Zhou, X. et al. Genetic deletion of low density lipoprotein receptor impairs sterol-
induced mouse macrophage ABCA1 expression. A new SREBP1-dependent
mechanism. J Biol Chem 283, 2129–2138 (2008).
23. Memczak, S. et al. Circular RNAs are a large class of animal RNAs with regulatory
potency. Nature 495, 333–338 (2013).
24. Rottiers, V. et al. Pharmacological Inhibition of a MicroRNA Family in
Nonhuman Primates by a Seed-Targeting 8-Mer AntimiR. Sci Transl Med 5,
212ra162 (2013).
25. Copeland, N. G., Jenkins, N. A. & Court, D. L. Recombineering: a powerful new
tool for mouse functional genomics. Nat Rev Genet 2, 769–779 (2001).
26. Horiguchi, M. et al. Fibulin-4 conducts proper elastogenesis via interaction with
cross-linking enzyme lysyl oxidase. Proc Natl Acad Sci U S A 106, 19029–19034
(2009).
27. Morita, M. et al. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in
association with erythropoietin. EMBO J 22, 1134–1146 (2003).
28. Seglen, P. O. Preparation of isolated rat liver cells. Methods Cell Biol 13, 29–83
(1976).
29. Zhang, Z. et al. Expression of cholesteryl ester transfer protein in human
atherosclerotic lesions and its implication in reverse cholesterol transport.
Atherosclerosis 159, 67–75 (2001).
30. Horie, T. et al. Acute doxorubicin cardiotoxicity is associated with miR-146a-
induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 87, 656–664
(2010).
31. Usui, S., Kakuuchi, H., Okamoto, M., Mizukami, Y. & Okazaki, M. Differential
reactivity of two homogeneous LDL-cholesterol methods to LDL and VLDL
subfractions, as demonstrated by ultracentrifugation and HPLC. Clin Chem 48,
1946–1954 (2002).
Acknowledgments
We thank Neal G. Copeland (Institute of Molecular and Cell Biology, Singapore) for the
defective prophage l-Red recombination system; Junji Takeda (Osaka University, Osaka,
Japan) and Kosuke Yusa (Osaka University, Osaka, Japan) for the plasmid used for the
construction of the targeting vector; Ken-ichi Yamamura (Kumamoto University,
Kumamoto, Japan) and KimiAraki (KumamotoUniversity) forAyu-1Cre expressingmice.
This work was supported in part by grants from the Japan Society for the Promotion of
Science, by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture,
Sports, Science, and Technology of Japan (to T. Kimura, T. Kita, K.H., T.H., and K.O.), by a
Grant-in-Aid for Scientific Research on Innovative Areas ‘‘Crosstalk between
transcriptional control and energy pathways, mediated by hubmetabolites’’(3307) from the
Ministry of Education, Culture, Sports, Science and Technology of Japan (to K.O.), by
Otsuka Pharmaceutical Co., Ltd. - Kyoto University SRP Program (to T. Kimura, T. Kita,
M.Y., T.H., and K.O.), by grants from Banyu Life Science Foundation International, Takeda
Memorial Foundation, Suzuken Memorial Foundation, Sakakibara Memorial Foundation,
Japan Foundation of Applied Enzymology, SENSHINMedical Research Foundation, Kowa
Life Science Foundation, and ONOMedical Research Foundation (to T.H.), and by grants
from ONO Medical Research Foundation, the Cell Science Research Foundation,
Daiichi-Sankyo Foundation of Life Science, and Takeda Memorial Foundation (to K.O.).
Author contributions
T.H., T.N. and K.O. designed the project; T.H., T.N., O.B., Y.K., T.N., M.N., S.U., M.I., F.N.,
Y.I., S.K. and N.S. performed experiments; T.H., T.N., N.Y., H.S., T.N., K.H., N.K., M.Y.,
T.K., T.K. and K.O. analyzed and interpreted data; and T.H., T.N. and K.O. prepared the
manuscript.
Additional information
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: The authors declare no competing financial interests.
How to cite this article:Horie, T. et al.MicroRNA-33b knock-inmice for an intron of sterol
regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo. Sci. Rep. 4,
5312; DOI:10.1038/srep05312 (2014).
This work is licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are included in the
article’s Creative Commons license, unless indicated otherwise in the credit line; if
the material is not included under the Creative Commons license, users will need
to obtain permission from the license holder in order to reproduce thematerial. To
view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5312 | DOI: 10.1038/srep05312 7
